Repligen raising $100m may signal more M&A activity to come

By Dan Stanton contact

- Last updated on GMT

Image: iStock/george tsartsianidis
Image: iStock/george tsartsianidis

Related tags: Chromatography

An offering of $100m of convertible notes expected to close today could be used to fund future acquisitions, according to Repligen.

The Waltham, Massachusetts-based bioprocessing company announced a public offering last week of around $100m (€89m) of convertible senior notes due 2021, and according to its prospectus the cash raised could “fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.”

While the firm says it is yet to have entered into any such agreement, the offering fits in with Repligen’s M&A strategy which has seen the firm diversify its portfolio from Protein A ligand manufacturer to an upstream and downstream equipment supplier to the biomanufacturing industry.

“Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition,”​ the prospectus added. “We will selectively pursue acquisitions of innovative technologies and products.”

Last month​ the $22.5m acquisition of German life sciences firm Atoll beefed up Repligen’s pre-packed chromatography column portfolio, while in 2014​ the firm acquired the bioprocessing assets of Refine Technology adding the Alternating Tangenital Flow (ATF) system to its upstream offering.

However, the firm remains the major producer of Protein A ligands, used to make Protein A resin which is highly effective chromatography media used to capture monoclonal antibodies during bioproduction.

Recently Repligen has extended long-term ligand supply contracts with both GE Healthcare​ and Purolite​.

The delivery of the notes is expected to be made to investors in book-entry form today and the notes are set to mature on June 1, 2021. Investment bank Jefferies is acting as the sole book-running manager.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us


View more